title: Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors.
abstract: Tumor necrosis factor-? (TNF-?) inhibitors are biologic agents that are currently in wide use for the treatment of psoriasis as well as other inflammatory diseases. Following reports of thrombocytopenia as a potential adverse effect of anti-TNF-? therapy, we performed a retrospective study to determine the frequency of thrombocytopenia, defined as a platelet count <50x109 cells/L, in a cohort of 187 psoriatic patients treated with anti-TNF-? agents over a nine-year period. Although none of our patients met serologic criteria for thrombocytopenia or displayed clinical manifestations of thrombocytopenia, two patients developed platelet counts below 100×109 cells/L. Thrombocytopenia induced by anti-TNF-? agents is a potential adverse effect, it is a rare occurrence that will require further investigation in large, placebo-controlled, double-blind, prospective studies.
authors.affiliation: Department of Dermatology, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Meng
authors.initials: M
authors.lastname: Chen
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Holland
authors.forename: Mohsin R
authors.initials: MR
authors.lastname: Mir
authors.forename: Michael G
authors.initials: MG
authors.lastname: Wong
authors.forename: Brian P
authors.initials: BP
authors.lastname: Kelley
authors.forename: Kelli D
authors.initials: KD
authors.lastname: Grim
authors.forename: Sunaina S
authors.initials: SS
authors.lastname: Bhuchar
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hsu
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001772:Blood Cell Count; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000453:epidemiology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept; C472181:efalizumab